(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 June 2006 (01.06.2006)

PCT

(10) International Publication Number
WO 2006/056845 A1

(51) International Patent Classification:
C07D 231/14 (2006.01) *A61P 3/06* (2006.01)
C07D 405/06 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/IB2005/003461

(22) International Filing Date:
14 November 2005 (14.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/630,481 23 November 2004 (23.11.2004) US

(71) Applicant *(for all designated States except US)*: **WARNER-LAMBERT COMPANY LLC** [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **CHOI, Chulho** [US/KR]; Pfizer Global Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **HUTCHINGS, Richard, H.** [US/US]; Pfizer Global Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **PFEFFERKORN, Jeffrey, A.** [US/US]; Pfizer Global Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **BOWLES, Daniel, Merritt** [US/US]; Pfizer Global Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **PARK, William, Keun, Chan** [US/US]; Pfizer Global Research & Development, 2800 Plymouth Road, Ann Arbor, MI 48105 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** 7-(2H-PYRAZOL-3-YL)-3, 5-DIHYROXY-HEPTANOIC ACID DERIVATIVES AS HMG CO-A REDUCTASE INHIBITORS FOR THE TREATMENT OF LIPIDEMIA

(57) **Abstract:** The present invention provides compounds of the formula (I), (IV) and (V) and intermediates of the formuale (VI) and (VII): (I), (IV), (V), (VI), (VII). wherein: R_1 is hydrogen, halogen, C_1-C_7 alkyl, C_3-C_8 cycloalkyl, aryl, aralkyl, heteroaryt, or heteroaralkyl; more specifically, R_1 is C_1-C_7 alkyl or C_3-C_8 cycloalkyl; even more specifically, R_1 is isopropyl; where alkyl, cycloalkyt, aryl, aralkyt, heteroaryl, or heteroaralkyl of R_1 is optionally substituted, R_2 is hydrogen, halogen, C_1-C_7 alkyl, C_3-C_8 cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, NC-, $R_{2b}R_{2a}NCO(CH_2)_n$ -, $R_{2b}R_{2a}NS(O)_n$-, $R_{2c}S(O)_n$-, $R_{2b}R_{2a}N(CH_2)_n$-, R_{2b}-J-$C(O)NR_{2a}(CH2)_n$-, R_{2b}-J-$SO_2NR_{2a}(CH_2)_n$-, R_{2b}-J-$SONR_{2a}(CH_2)_n$, $R^7OOC(CH_2)_n$-, or $R^7CO(CH_2)_n$-; more specifically, R_2 is $R_{2b}R_{2a}NCO(CH_2)_n$-; even more specifically, R_2 is $R_{2b}R_{2a}$ NCO-; where alkyl, cycloalkyl, aryl , aralkyl, heteroaryl, or heteroaralkyl of R_2 is optionally substituted, R_3 is hydrogen, $C_{1\text{-}6}$ aikyl, $C_{3\text{-}6}$necycloafkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; more specifically, R_3 is aryl; even more specifically, R_3 is phenyl or p-fluorophenyl; where alkyl, cycloalkyl, aryl, aralkyl, heteroaryt, or beteroaralkyd of A_3 is opltianally substituted and is a bond or is absent. The other substituents are defined in the claims. The present invention relates to compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents. Moree specifically, the present invention concerns certain potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase ("HMG CoA reciuctase"). The compounds are useful for the treatement of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis.

WO 2006/056845 A1